ga naar hoofdinhoud
Vademecum systeemtherapie Gastro-enterologische tumoren Colorectaal carcinoom (CRC) Literatuur en richtlijnen
Voorlezen

Literatuur

  1. Grothey A et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018; 378(13):1177-88
  2. Simkens LH et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385(9980):1843-52
  3. Goey KKH et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017; 28(9):2128-34
  4. Hegewisch-Becker S. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015; 16(13):1355-69
  5. Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371(9617): 1007-16
  6. Loupakis F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014; 371(17):1609-18
  7. Gruenberger T et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015; 26(4):702-8
  8. Xu RH et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. The Lancet Oncology. 2018;19(5):660-71
  9. Schmiegel W. et al. Capecitabine / irinotecan or capecitabine / oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. 2013; 24(6):1580-7
  10. Yan TD et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27(36):6237-42
  11. Sugarbaker PH. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia. Ann Surg Oncol. 2010; 17(6):1710-2
  12. Bahadoer RR et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2021; 22(1):29-42
  13. Dijkstra EA et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemo­radio­therapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023 Oct 1; 278(4):766-772 
  14. Prager GW et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023; 388:1657-67
  15. Amado R et al. Association of KRAS mutational status and efficacy of panitumumab monotherapy for the treatment (tx) of metastatic colorectal cancer (mCRC): results of pooled data from 4 clinical studies. Annals of Oncology 2008; 19(8):126-126
  16. Christos S et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765
  17. Cremolini C et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology 2020; 20(4)497-507
  18. Tougeron D et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study. J Natl Cancer Inst. 2016 Feb 1; 108(7)
  19. Grothey A et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018; 378:1177-1188
  20. André T et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015; 33:4176-4187
  21. André T et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. The Lancet 2025; 405(10476):383-395
  22. André T et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383(23):2207-2218

Commissie BOM adviezen

Ga naar de commissie BOM adviezen over Colorectaal carcinoom.

Richtlijnen

Ga naar de richtlijn Colorectaal carcinoom in de FMS richtlijnen­database.

Ga naar de richtlijn Colon cancer van de NCCN. 

Ga naar de richtlijn Erfelijke darmkanker: Lynch syndroom, polyposis en familiair darmkanker in de FMS richtlijnen­database.

Ga naar de richtlijn Colorectaal carcinoom van VKGN - StOET.